Combination therapy: Opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines

Advanced Drug Delivery Reviews

Volumn 61, Issue 13, 2009, Pages 1203-1213

  Greco, Francesca ^a   Vicent, María J ^b  

^a UNIVERSITY OF READING   (United Kingdom)

^b CENTRO DE INVESTIGACIÓN PRÍNCIPE FELIPE   (Spain)

Author keywords

Cancer; Combination therapy; Nanomedicine; Polymer therapeutics; Polymer conjugate; Targeted drug delivery

Indexed keywords

CANCER; COMBINATION THERAPY; NANOMEDICINE; POLYMER THERAPEUTICS; TARGETED DRUG DELIVERY;

DRUG DELIVERY; LIGANDS; MEDICAL NANOTECHNOLOGY; POLYMERS;

FUNCTIONAL POLYMERS;

ANASTROZOLE; ANTINEOPLASTIC AGENT; BETA1A INTERFERON; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; DRUG CARRIER; FLUOROURACIL; FOLINIC ACID; GASTRIN; GLATIRAMER; GLUCAGON LIKE PEPTIDE 1; GOSERELIN; METHOTREXATE; N (2 HYDROXYPROPYL)METHACRYLAMIDE; NAVELBINE; PACLITAXEL; POLYGLUTAMIC ACID; POLYMER; PREDNISONE; RITUXIMAB; TAMOXIFEN; TRASTUZUMAB; UNINDEXED DRUG; VINCRISTINE; ZOLEDRONIC ACID;

ADJUVANT THERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; DIABETES MELLITUS; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG POTENTIATION; DRUG TARGETING; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE SCLEROSIS; NANOMEDICINE; NONLYMPHATIC LEUKEMIA; OVARY CANCER; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NANOMEDICINE; NANOPARTICLES; NEOPLASMS; POLYMERS;

EID: 70349978292     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.05.006     Document Type: Review

References (106)

1. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 4 (2005) 145-160
2. Amin C., Mackman N., and Key N.S. Microparticles and cancer. Pathophysiol. Haemost. Thromb. 36 (2008) 177-183
3. Harris J.M., and Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2 (2003) 214-221
4. Veronese F.M., and Harris J.M.E. Peptide and Protein PEGylation III: advances in chemistry and clinical applications. Adv. Drug Deliv. Rev. 60 (2008) 1-88 (whole volume)
5. http://www.ctiseattle.com.
6. Gee J.M.W., Howell A., Gullick W.J., Benz C.C., Sutherland R.L., Santen R.J., Martin L.A., Ciardiello F., Miller W.R., Dowsett M., Barrett-Lee P., Robertson J.F.R., Johnston S.R., Jones H.E., Wakeling A.E., Duncan R., and Nicholson R.I. Consensus statement Endocrin. Rel. Cancer 12 (2005) S1-S7
7. Broxterman H.J., and Georgopapadakou N.H. Anticancer therapeutics: "addictive" targets, multi-targeted drugs, new drug combinations. Drug Resis. Updat. 8 (2005) 183-197
8. de Gaetano Donati K., Rabagliati R., Iacoviello L., and Cauda R. HIV infection, HAART, and endothelial adhesion molecules: current perspectives. Lancet Infect. Dis. 4 (2004) 213-222
9. Orjuela P., Gonzalez I., and Osorio L. Combination therapy as a strategy to prevent antimalarial drug resistance. Biomédica 24 (2004) 423-437
10. http://clinicaltrials.gov.
11. Suarez-Pinzon W.L., Power R.F., Yan Y., Wasserfall C., Atkinson M., and Rabinovitch A. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57 (2008) 3281-3288
12. In: Perry M.C. (Ed). The Chemotherapy Source Book (1992), Williams & Wilkins, Maryland USA
13. Tanabe M., Ito Y., Tokudome N., Sugihara T., Miura H., Takahashi S., Seto Y., Iwase T., and Hatake K. Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes. Breast Cancer 12 (2009) 1-6
14. Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer act. Gyn. Oncol. 112 (2009) 275-281
15. Berhoune M., Banu E., Scotte F., Prognon P., Oudard S., and Bonan B. Therapeutic strategy for treatment of metastatic non-small cell lung cancer. Annals Pharmacother. 42 (2008) 1640-1652
16. Honecker F., Kollmannsberger C., Quietzsch D., Haag C., Schroeder M., Spott C., Hartmann J.T., Baronius W., Hempel V., Kanz L., and Bokemeyer C. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs 13 (2002) 497-503
17. Akeson M., Zetterqvist B.-M., Dahllöf K., Brännström M., and Horvath G. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up. Acta Obstet. Gynecol. Scand. 87 (2008) 1343-1352
18. Pearson O.H., Hubay C.A., Gordon N.H., Marshall J.S., Crowe J.P., Arafah B.M., and McGuire W. Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer. Cancer 64 (1989) 1819-1823
19. Logman J.F., Heeg B.M., Botteman M.F., Kaura S., and van Hout B.A. Economic evaluation of zoledronic acid for the prevention of fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the United Kingdom, ASCO. Breast Cancer Symp. vol. 177 (2008)
20. Shapiro C.L., Halabi S., Gibson G., Weckstein D.J., Kirshner J., Sikov W.M., Winer E.P., Hudis C.A., Isaacs C., Weckstein D., Schilsky R.L., and Paskett E. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC): first results from CALGB trial 79809. J. Clin. Oncol. 26 (2008) (May 20 suppl, abstr 512)
21. Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Poestlberger S., Menzel C., Jakesz R., Kubista E., Marth C., and Greil R. On behalf of the ABCSG, Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: first efficacy results from ABCSG-12. J. Clin. Oncol. 26 (2008) (May 20 suppl., abstr LBA4)
22. Gnant M., Mlineritsch B., Schippinger W., Luschin-Ebengreuth G., Poestlberger S., Menzel C., Jakesz R., Kubista E., Marth C., and Greil R. On behalf of the ABCSG, Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 9 (2008) 840-849
23. Metro G., Mottolese M., and Fabi A. HER-2-positive metastatic breast cancer: trastuzumab and beyond. Expert Opin. Pharmacother. 9 (2008) 2583-2601
24. Bharthuar A., Egloff L., Becker J., George M., Lohr J.W., Deeb G., and Iyer R.V. Rituximab-based therapy for gemcitabine-induced hemolytic uremic syndrome in a patient with metastatic pancreatic adenocarcinoma: a case report. Cancer Chemother. Pharmacol. 62 (2008) 1-5
25. Van Poppel H. Treatment of advanced and metastatic renal cancer: a revolution?. Eur. Urol. Suppl. 8 (2009) 483-488
26. Rugo H.S. Bevacizumab in the treatment of breast cancer: rationale and current data. Oncologist 9 Suppl 1 (2004) 43-49
27. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., Shenkier T., Cella D., and Davidson N.E. Paclitaxel plus Bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357 (2007) 2666-2676
28. Jones D. Avastin-Tarceva combination fails in lung cancer. Nat. Biotechnol. 27 (2009) 108-109
29. Wendel H.-G., Stanchina E., Fridman J.S., Malina A., Ray S., Kogan S., Cordon-Cardo C., Pelletier J., and Lowe S.W. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 482 (2004) 332-337
30. Lane D. Designer combination therapy for cancer. Nat. Biotechnol. 24 (2006) 163-164
31. Adams G.P., and Weiner L.M. Monoclonal antibody therapy of cancer. Nat. Biotechnol. 23 (2005) 1147-1157
32. Gulley J.L., Arlen P.M., Bastian A., Morin S., Marte J., Beetham P., Tsang K.-Y., Yokokawa J., Hodge J.W., Menard C., Camphausen K., Coleman N., Sullivan F., Steinberg S.M., Schlom J., and William. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin. Cancer Res. 11 (2005) 3353-3362
33. Chakraborty M., Abrams S.I., Coleman C.N., Camphausen K., Schlom J., and Hodge J.W. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine mediated T-cell killing. Cancer Res. 64 (2004) 4328-4337
34. Ringsdorf H. Structure and propreties of pharmacologically active polymers. J. Polym. Sci., Polym. Symp. 51 (1975) 135-153
35. Duncan R., Seymour L.C.W., Scarlett L., Lloyd J.B., Rejmanova P., and Kopeček J. Fate of N-(2-hydroxypropyl)methacrylamide copolymers with pendant galactosamine residues after intravenous administration to rats. Biochim. Biophys. Acta 880 (1986) 62-71
36. Duncan R., Seymour L.W., O'Hare K.B., Flanagan P., Wedge S., Ulbrich K., Strohalm J., Subr V., Spreafico F., Grandi M., Ripamonti M., Farao M., and Suarato A. Preclinical evaluation of polymer-bound doxorubicin. J. Control. Release 19 (1992) 331-346
37. Vasey P.A., Kaye S.B., MorrisonC R., Twelves P.W., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtless S., Fraier D., Frigerio E., and Cassidy J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res. 5 (1999) 83-94
38. Meerum Terwogt J.M., ten Bokkel Huinink W.W., Schellens J.H.M., Schot M., Mandjes I., Zurlo M., Rocchetti M., Rosing H., and Beijnen K.J.H. Phase I clinical and pharmacokinetic study of PNU166945, a novel water soluble polymer conjugated prodrug of paclitaxel. Anticancer Drug Des. 12 (2001) 315-323
39. TM (AP5346), a DACH-platinum HPMA polmer prodrug. Proc. Int Symp. Polymer Therapeutics (2007) 41
40. http://www.accesspharma.com.
41. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6 (2006) 688-701
42. Vicent M.J., and Duncan R. Polymer conjugates: nanosized medicines for treating cancer. Trends Biotechnol. 24 (2006) 39-47
43. Satchi-Fainaro R., Duncan R., and Barnes C.M. Polymer therapeutics for cancer: current status and future challenges. Adv. Poym. Sci. 193 (2006) 1-65
44. Li C., and Wallace S. Polymer-drug conjugates: recent development in clinical oncology. Adv. Drug Deliv. Rev. 60 (2008) 886-898
45. Chipman S.D., Oldham F.B., Pezzoni G., and Singer J.W. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate. Int. J. Nanomed. 1 (2006) 375-383
46. Singer J.W. Paclitaxel poliglumex (XYOTAX™, CT-2103): a macromolecular taxane. J. Control. Release 109 (2005) 120-126
47. Maeda H. Polymer conjugated macromolecular drugs for tumor-specific targeting. In: Domb A.J. (Ed). Polymeric Site-specific Pharmacotherapy (1994), John Wiley and Sons Ltd, USA 95-116
48. Minko T., Kopečková P., Pozharov V., and Kopeček J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Control. Release 54 (1998) 223-233
49. Ríhová B., Strohalm J., Prausová J., Kubácková K., Jelínková M., Rozprimová L., Sírová M., Plocová D., Etrych T., Subr V., Mrkvan T., Kovár M., and Ulbrich K. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. J. Control. Release 28 (2003) 1-16
50. Sirova M., Strohalm J., Subr V., Plocova D., Rossmann P., Mrkvan T., Ulbrich K., and Rihova B. Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice. Cancer Immunol. Immunother. 56 (2007) 35-47
51. Greco F., and Vicent M.J. Polymer-drug conjugates: current status and future trends. Frontiers Biosci. 13 (2008) 2744-2756
52. Haag R., and Kratz F. Polymer therapeutics: concepts and applications. Angew. Chem. Int. Ed. 45 (2006) 1198-1215
53. Verschraegen C.F., Skubitz K., Daud A., Kudelka A.P., Rabinowitz I., Allievi C., Eisenfeld A., Singer J.W., and Oldham F.B. A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 63 (2009) 903-910
54. Langer C.J., O'Byrne K.J., Socinski M.A., Mikhailov S.M., and Lesniewski-Kmak K. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naive advanced non-small cell lung cancer. J. Thorac. Oncol. 3 (2008) 623-630
55. Dipetrillo T.A., Milas L., and Evans D. Paclitaxel poliglumex (PPX-xyotax) and concurrent radiation for esophageal and gastric cancer - a phase I study. J. Clin. Oncol. 29 (2006) 376-379
56. Ke S., Milas L., Charnsangavej C., Wallace S., and Li C. Potentiation of radioresponse by polymer-drug conjugates. J. Control. Release 74 (2001) 237-242
57. Lammers T., Peschke P., Kühnlein R., Subr V., Ulbrich K., Debus J., Huber P., Hennink W., and Storm G. Effect of radiotherapy and hyperthermia on the tumor accumulation of HPMA copolymer-based drug delivery systems. J. Control. Release 117 (2007) 333-341
58. Lammers T., Subr V., Peschke P., Kühnlein R., Hennink W.E., Ulbrich K., Kiessling F., Heilmann M., Debus J., Huber P.E., and Storm G. Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br. J. Cancer 99 (2008) 900-910
59. Shiah J.G., Sun Y., Kopečková P., Peterson C.M., Straight R.C., and Kopeček J. Combination chemotherapy and photodynamic therapy of targetable N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin/mesochlorin e(6)-OV-TL 16 antibody immunoconjugates. J. Control. Release 74 (2001) 249-253
60. Hongrapipat J., Kopečková P., Liu J., Prakongpan S., and Kopeček J. Combination chemotherapy and photodynamic therapy with fab' fragment targeted HPMA copolymer conjugates in human ovarian carcinoma cells. Mol. Pharmacol. 5 (2008) 696-709
61. Fang J., Sawa T., Akaike T., Greish K., and Maeda H. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int. J. Cancer 109 (2004) 1-8
62. Khandare J.J., Chandna P., Wang Y., Pozharov V.P., and Minko T. Novel polymeric prodrug with multivalent components for cancer therapy. J. Pharmacol. Exp. Ther. 317 (2006) 929-937
63. Khandare J., and Minko T. Polymer-drug conjugates: progress in polymeric prodrugs Prog. Polym. Sci. 31 (2006) 359-397
64. Seymour L.W., Ferry D., Anderson D., Julyan P., Poyner R., Doran J., Young A., Burtles S., and Kerr D. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 20 (2002) 1668-1676
65. J.G.W. Kosternik, W. Helfrich, L.F.M.H. De Leij, Strategies for specific drug targeting to tumour cells, in: Drug targeting. organ-specific strategies, Weinheim, Germany: Wiley-VCH (Eds) 2001 pp. 199-231.
66. Vicent M.J., Greco F., Paul A., Griffiths P.C., Nicholson R.I., and Duncan R. Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew. Chem. Int. Ed. 44 (2005) 4061-4066
67. Greco F., Vicent M.J., Penning N.A., Nicholson R.I., and Duncan R. HPMA copolymer-aminoglutethimide conjugates inhibit aromatase in MCF-7 cell lines. J. Drug Target. 13 (2005) 459-470
68. Greco F., Vicent M.J., Gee S., Jones A.T., Gee J., Nicholson R.I., and Duncan R. The mechanism of enhanced cytotoxicity of HPMA copolymer-DOX-AGM in breast cancer cells. J. Control. Release 117 (2007) 28-39
69. Pasut G., Scaramuzza S., Schiavon O., Mendichi R., and Veronese F.M. PEG-epirubicin conjugates with high drug loading. J. Bioact. Compat. Polym. 20 (2005) 213-230
70. Santucci L., Mencarelli A., and Renga B. Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin. FASEB J. 20 (2006) 765-773
71. Santucci L., Mencarelli A., Renga B., Ceccobelli D., Pasut G., Veronese F., Distrutti E., and Fiorucci M.D. Cardiac safety and anti-tumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. Anticancer Drugs 18 (2007) 1081-1091
72. th Annual Mtg. Control. Rel. Soc. (2008) 35
73. Satchi-Fainaro R., Puder M., Davies J.W., Tran H.T., Sampson D.A., Greene A.K., Corfas G., and Folkman J. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med. 10 (2004) 255-261
74. Satchi-Fainaro R., Mamluk R., Wang L., Short S.M., Nagy J.A., Feng D., Dvorak A.M., Dvorak H.F., Puder M., Mukhopadhyay D., and Folkman J. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell 7 (2005) 251-261
75. http://www.syndevrx.com.
76. E. Segal, H. Pan, P. Ofek, T. Udagawa, P. Kopečková, J. Kopeček, R. Satchi-Fainaro, Targeting Angiogenesis-Dependent Calcified Neoplasms Using Combined Polymer Therapeutics, PLoS ONE 4 (4) (2009) e5233.
77. K. Miller, R. Erez, E. Segal, D. Shabat, R. Satchi-Fainaro Targeting Bone Metastases with a Novel Bi-Specific Anticancer and Anti-Angiogenic Polymer-Alendronate-Taxane Conjugate, Angew. Chem. Int. Ed. 48 (2009) 2949-2954.
78. T. Lammers, V. Subr, K. Ulbrich, P. Peschke, P.E. Huber, W.E. Hennink, G. Storm, Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers, Biomaterials 30 (2009) 3466-3475.
79. Krakovicova H., Etrych T., and Ulbrich K. HPMA-based polymer conjugates with drug combination. Eur. J. Pharm. Sci. 37 (2009) 405-412
80. Bae Y., Diezi T.A., Zhao A., and Kwon G.S. Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J. Control. Release 122 (2007) 324-330
81. Satchi R., Connors T.A., and Duncan R. PDEPT: polymer-directed enzyme prodrug therapy I. HPMA copolymer-cathepsin B and PK1 as a model combination. Br. J. Cancer 85 (2001) 1070-1076
82. Satchi-Fainaro R., Hailu H., Davies J.W., Summerford C., and Duncan R. PDEPT: Polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination. Bioconjug. Chem 14 (2003) 797-804
83. Satchi-Fainaro R., Wrasidlo W., Lode H.N., and Shabat D. Synthesis and characterization of a catalytic antibody-HPMA copolymer-conjugate as a tool for tumor selective prodrug activation. Bioorg. Med. Chem. 10 (2002) 3023-3029
84. Duncan R., Gac-Breton S., Keane R., Musila R., Sat Y.N., Satchi R., and Searle F. Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J. Control. Release 74 (2001) 135-146
85. R. Satchi-Fainaro, R. Duncan, PELT: Polymer enzyme liposome therapy. HPMA copolymer-phospholipase C and Doxil/ Daunoxomes as a novel combination. (unpublished data).
86. rd Annual Mtg. Control. Release Soc. 33 (2006) 660
87. th Int. Symp. Polymer Therapeutics: From Lab to clinic (2008) 96
88. http://www.celator.ca.
89. Duncan R. N-(2-Hydroxypropyl) methacrylamide copolymer conjugates. In: Kwon G.S. (Ed). Polymeric Drug Delivery System (2005), Marcel Dekker, Inc, New York 1-92
90. Duncan R., Hume I.C., Yardley H.J., Flanagan P.A., Ulbrich K., Subr V., and Strohalm J. Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N-(2-hydroxypropyl) methacrylamide copolymers. J. Control. Release 16 (1991) 121-136
91. Bhatt R., de Vries P., Tulinsky J., Bellamy G., Baker B., Singer J.W., and Klein P. Synthesis and in vivo antitumor activity of poly(L-glutamic acid) conjugates of 20(S)-camptothecin. J. Med. Chem. 46 (2003) 190-193
92. Jain N.K., and Asthana A. Dendritic systems in drug delivery applications. Expert Opin. Drug. Deliv. 4 (2007) 495-512
93. Lee C.C., MacKay J.A., and Frechet J.M.J. Designing dendrimers for biological applications. Nat. Biotechnol. 23 (2005) 1517-1526
94. Kainthan R.K., Hester S.R., and Levin E. In vitro biological evaluation of high molecular weight hyperbranched polyglycerols. Biomaterials 28 (2007) 4581-4590
95. In: Mishra M.K., and Kobayashi S. (Eds). Star and Hyperbranched Polymers (1999), Marcel Dekker, New York
96. Duncan R., and Izzo L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 57 (2005) 2215-2237
97. Vicent MJ M.J. Polymer-drug conjugates as modulators of cellular apoptosis. AAPS J. 9 (2007) E200-E207
98. Schluter A.D. A covalent chemistry approach to giant macromolecules with cylindrical shape and an engineerable interior and surface. Top. Curr. Chem. 245 (2005) 151-191
99. Vicent M.J., Dieudonne L., Carbajo R.J., and Pineda-Lucena A. Polymer conjugates as therapeutics: future trends, challenges and opportunities. Expert Opin. Drug. Deliv. 5 (2008) 593-614
100. Griffiths P.C., Paul A., Khayat Z., Wan K.W., King S.M., Grillo I., Schweins R., Ferruti P., franchini J., and Duncan R. Understanding the mechanism of action of poly(amidoamine)s as endosomolytic polymers: correlation of physicochemical and biological properties. Biomacromolecules 5 (2004) 1422-1427
101. Paul A., Vicent M.J., and Duncan R. Using small-angle neutron scattering to study the solution conformation of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates. Biomacromolecules 8 (2007) 1573-1579
102. Vicent M.J., and Pérez-Payá E. Poly-L-glutamic acid (PGA) aided inhibitors of apoptotic protease activating factor 1 (Apaf-1): an antiapoptotic polymeric nanomedicine. J. Med. Chem. 49 (2006) 3763-3765
103. 1H-NMR of polymer conjugates with the anticancer drug doxorubicin. Magn. Reson. Chem. 35 (1997) 2-8
104. Hentschel J., ten Cate M.G.J., and Borner H.G. Peptide-guided organization of peptide-polymer conjugates: expanding the approach from oligo- to polymers. Macromolecules 40 (2007) 9224-9232
105. Klee J.E. Review: mass spectrometry of step-growth polymers. Eur. J. Mass Spectrom. 11 (2005) 591-610
106. Mendichi R., Rizzo V., Gigli M., and Schieroni A.G. Fractionation and characterization of a conjugate between a polymeric drug-carrier and the antitumor drug camptothecin. Bioconjug. Chem. 13 (2002) 1253-1258